Dr. Nevin's research has focused primarily on the adverse effects of quinoline antimalarials. Dr. Nevin’s work has been instrumental in improving policymakers’ understanding of the potential for long-lasting and permanent neurologic and psychiatric effects from quinoline antimalarials, as exemplified by a recent FDA "black box" warning.

Dr. Nevin has testified before the U.S. Senate, the Australian Senate, the U.K. Parliament, and the Canadian Parliament, and has provided evidence to the Irish Department of Defence on quinoline antimalarials' lasting neurologic and psychiatric adverse effects confounding the diagnosis and management of posttraumatic stress disorder and traumatic brain injury. Dr. Nevin's work has contributed directly to militaries in the U.S., Canada, the U.K., and Ireland discontinuing their decades-long policies of first-line use of these antimalarials, in favor of safer and better-tolerated alternatives.

Dr. Nevin was first to publish a clinical description of quinism, the permanent disorder of brain and brainstem dysfunction caused by the use of quinoline antimalarials, and to publish descriptions of certain of its features, including limbic encephalopathy and neurotoxic vestibulopathy. Dr. Nevin has also collaborated on the first review of the adverse effectes of quinoline antimalarials published in the forensic psychiatry literature, and published the first case report of a former U.S. military servicemember awarded disability compensation for their long-lasting adverse psychiatric effects .